Amplicore is an early-stage biopharmaceutical company based in Cincinnati, OH, developing locally delivered and minimally invasive therapeutics for musculoskeletal diseases. The company is advancing two lead preclinical candidates, AM3101 and AM1101. AM1101 is being developed as a treatment for osteoarthritis to reduce joint pain, inhibit cartilage degradation, and promote tissue regeneration. Amplicore is leveraging a Department of Defense grant-supported study on healing of acute meniscal tear after surgical repair. The company intends to use the proceeds of its seed financing to complete preclinical development of its two lead products and position itself for a subsequent financing. Amplicore is led by Founder, President, and CEO Dr. Chia-Ying (James) Lin.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2021